Secondary Prevention Medications for Post-PCI CAD Patient
This patient requires immediate initiation of comprehensive secondary prevention therapy including aspirin 75-100 mg daily (or clopidogrel if aspirin-intolerant), high-intensity statin therapy, and consideration of beta-blockers and ACE inhibitors/ARBs, as the absence of any medications represents a critical gap in evidence-based care that significantly increases risk of recurrent cardiovascular events and mortality. 1
Antiplatelet Therapy (Highest Priority)
Aspirin 75-162 mg daily is mandatory in all patients with coronary artery disease unless contraindicated, as this represents Class I, Level A evidence for reducing mortality and recurrent events. 1 The 2024 ESC guidelines specifically recommend aspirin 75-100 mg daily lifelong in patients with prior MI or revascularization. 1
If aspirin is not tolerated or contraindicated, clopidogrel 75 mg daily is the recommended alternative (Class I, Level B evidence). 1
Critical timing consideration: Since you mention the patient is "not currently on any medicines," you need to determine when the PCI occurred. If the PCI was within the past 6-12 months, dual antiplatelet therapy (DAPT) with both aspirin AND clopidogrel should have been prescribed and needs immediate initiation if still within that window. 1
For patients post-PCI with stenting, DAPT (aspirin plus clopidogrel 75 mg daily) is recommended for up to 6 months as the default strategy, with duration potentially shortened to 1-3 months if life-threatening bleeding risk exists. 1
Lipid-Lowering Therapy (Equal Priority)
High-intensity statin therapy is mandatory (Class I recommendation) in all patients with chronic coronary syndrome, regardless of baseline LDL levels. 1
Target LDL-C <100 mg/dL is the minimum goal, with consideration of <70 mg/dL for very high-risk patients (which this patient qualifies for given prior PCI). 1
The statin should be titrated to the highest tolerated dose to achieve these aggressive LDL targets. 1
If LDL goals are not met with maximally tolerated statin therapy, additional agents (ezetimibe, PCSK9 inhibitors) should be added. 2
Blood Pressure Management
Beta-blockers and ACE inhibitors (or ARBs if ACE inhibitors not tolerated) should be strongly considered as first-line antihypertensive agents in patients with CAD. 1, 2
Beta-blockers provide both anti-ischemic and prognostic benefits, particularly in patients with prior MI or reduced left ventricular function. 2
ACE inhibitors/ARBs reduce cardiovascular events and mortality in CAD patients, especially those with diabetes, hypertension, or left ventricular dysfunction. 1, 2
If beta-blockers or ACE inhibitors are not tolerated, calcium channel blockers are acceptable alternatives. 2
Additional Considerations
Assess for diabetes mellitus if not already done, as this patient requires coordinated care with lifestyle modifications including daily physical activity, weight management, and potentially metformin as first-line pharmacotherapy if diabetic. 1
Common pitfall: The fact that this patient is "asymptomatic and very active" does NOT negate the need for aggressive secondary prevention. 3 Absence of symptoms does not equate to absence of disease progression risk—these medications prevent future events (MI, death) rather than just treating symptoms. 2
Urgent action required: The complete absence of any medications in a post-PCI patient represents a serious treatment gap. Studies demonstrate that patients receiving guideline-directed medical therapy have significantly lower rates of major adverse cardiovascular events compared to those without optimal pharmacological treatment. 3 The 5-year MACE rate is reduced by approximately 11% with comprehensive secondary prevention. 3